Chinese Herbal Medicine Treatment as Adjunct Therapy for Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: Parkinson's disease (PD) is a prevalent and debilitating condition. Conventional medications cannot control all symptoms and may inflict adverse effects. A survey reported that Chinese herbal medicine (CHM) is frequently sought. Existing CHM trials were contradictory and often of poor quality due to a lack of methodological rigor. A national clinical guideline was drafted in China with diagnostic criteria and treatment strategy of Chinese medicine (CM) patterns subgroups of PD. The suggested CHM was found to exhibit a neuroprotective effect in in vitro and in vivo studies. This trial aims to preliminarily assess the effect of CHM prescribed based on pattern differentiation on PD symptoms and patients' quality of life, and evaluate the feasibility of the trial design for a future large-scale trial.

Methods: This trial will be a pilot assessor- and data analyst blind, add-on, randomised, controlled, pragmatic clinical trial. 160 PD patients will be recruited and randomised into treatment or control groups in a 1:1 ratio. The trial will be conducted over 32 weeks. PD patients in the treatment group will be stratified into subgroups based on CM pattern and receive CHM accordingly in addition to conventional medication (ConM). The control group will receive ConM only. The primary outcome will be part II of the Movement Disorder Society Sponsored Revision of Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Secondary outcomes will include part and total scores of MDS-UPDRS, domain and total scores of Non-motor symptom scale (NMSS). Adverse events will be monitored by monthly follow-ups and questionnaires. Mixed models will be used to analyse data by Jamovi and R.

Expected outcomes: The success of our trial will show that the pragmatic design with subgroup differentiation is feasible and can produce reliable results. It will also provide preliminary data of the effect of CHM on improving clinical outcomes and quality of PD patients. Data collected will be used to optimize the study design of the future large-scale clinical study.

Ethical clearance: Ethical clearance of this study was given by the Research Ethics Committee of Hong Kong Baptist University (REC/20-21/0206).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploratory Study of Effective Core Formula of Chinese Medicine to Treat Primary Insomnia

NCT01613183

Primary Insomnia

UNKNOWN NA

The Efficacy of Traditional Chinese Herbal Medicine for Dementia

NCT03838952

Dementia Alzheimer Disease

UNKNOWN NA

The Efficacy of Traditional Chinese Herbal Medicine for Alzheimer's Disease

NCT04249869

Alzheimer Disease

UNKNOWN PHASE1/PHASE2

An Examination of Blinding for Chinese Herbal Oral Liquid and Matched Placebo

NCT05483595

Placebo Evaluate

COMPLETED NA

Chinese Acupuncture for Chemobrain in Elderly Cancer Patients

NCT05876988

Chinese Acupuncture

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chinese herbal medicine treatment plus conventional medication

Participants will receive integrated medicine treatment combining Chinese herbal treatment, given in the form of granules, and conventional medication for 32 weeks. Patients will be differentiated into 4 subgroups based on their Chinese medicine pattern, and receive herbal treatment accordingly. An existing clinical pathway will guide the diagnosis and treatment of the Chinese medicine patterns. The four pattern subgroups are as follows:

1\) the "Phlegm-heat stirring Wind" subgroup; 2) the "Spleen-and Kidney-Yang" subgroup; 3) the "Internal Stirring of Yang and Wind" subgroup; and 4) the "Qi deficiency and stasis of Blood" subgroup

To resemble actual clinical practice, minor adjustment of herbal treatment will be possible and also adhere to the mentioned clinical guideline. The dosage of each herbal drug will follow the instructions of China Pharmacopeia.

Group Type EXPERIMENTAL

Conventional medication

Intervention Type DRUG

Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.

Chinese herbal medicine treatment

Intervention Type DRUG

1. Huanglian Wendan Decoction
2. Jin Gui Shen Qi Pill
3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction
4. Bu Yang Huan Wu Decoction

Conventional medication

Conventional medication for Parkinson's disease include levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.

Group Type ACTIVE_COMPARATOR

Conventional medication

Intervention Type DRUG

Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conventional medication

Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.

Intervention Type DRUG

Chinese herbal medicine treatment

1. Huanglian Wendan Decoction
2. Jin Gui Shen Qi Pill
3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction
4. Bu Yang Huan Wu Decoction

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. diagnosed with PD according to United Kingdom Parkinson's Disease Society Brain Bank (UKPDBB) diagnostic criteria
2. aged 18 to 80 years old
3. under stable ConM treatment with no alteration of dosage in the past 30 days

Exclusion Criteria

1. secondary PD or atypical parkinsonian disorder
2. used antidepressants in the previous month
3. with concurrent psychiatric, mood, or other neurological disorders
4. suicidal (with suicidal thoughts in the past year)
5. with concurrent severe disorders, such as cancer and myocardial infarction
6. participation in another Chinese herbal medicine clinical study
7. pregnant or breast-feeding
8. Hoehn and Yahr (H\&Y) stage 4 or above
9. liver and renal function derangement

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No